Carpio C, Bouabdallah R, Ysebaert L, et al. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020;135(13):996-1007.

doi:10.1182/blood.2021011546

Skip Nav Destination

ERRATUM| April 15, 2021

Carpio C, Bouabdallah R, Ysebaert L, et al. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020;135(13):996-1007.

Blood (2021) 137 (15): 2126.

https://doi.org/10.1182/blood.2021011546

In the author affiliations on page 996, Armando Santoro’s affiliation (affiliation no. 12) should read “Humanitas Clinical and Research Center—IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy.” The error has been corrected in the online version of the article.

2021

Carpio C, Bouabdallah R, Ysebaert L, et al. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020;135(13):996-1007.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Carpio C, Bouabdallah R, Ysebaert L, et al. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020;135(13):996-1007.

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only